One email a week. Catch up in five minutes.

The GammaRips weekly briefing — engine state, the latest Lab experiment, and what the pool's outcome data showed. No firehose, no FOMO.

We Use Cookies

We use cookies to enhance your experience, analyze site traffic, and for marketing purposes. By clicking "Accept," you agree to our use of cookies. Read our Privacy Policy.

RVMD

Name: RVMD overnight options flow scan record, 2026-08-24
Creator: GammaRips

BULL

2026-08-24

Overnight Scan Record · Healthcare

See the 2026-08-24 Morning Briefing

This is one row from the GammaRips nightly scan of about 3,500 optionable US stocks, tracked to its outcome. What membership means depends on the scan date. For scan dates from 2026-08-24, it is a liquidity rank: the 100 most liquid names, bullish only. For earlier scan dates, the scan selected on unusual options activity and included bearish names. The two sets are not one population. Data, not a recommendation. New here? See how the pool is built → Or put your AI agent on this data →

Score

8/10

Descriptive context. Not a quality rank and not a forecast.

Move

1.1%

Flow

$4.7M

AI Analysis

Model-written context on what the scan saw that night. It is context, not advice and not a trade instruction.

RVMD BULL $230C Sep 18 '26. The institutional flow shows significant premium concentration at the out-of-the-money $230 strike for September 2026, pointing to a highly directional, long-term bullish stance aligned with the company's advancing clinical oncology pipeline and the RASolve 308 lung cancer trial progression. The underlying stock is consolidating near its 52-week highs, exhibiting robust technical support. Risk factor: Biotech developmental delays or clinical trial data underperformance represent the primary sources of potential downside volatility for this pre-revenue setup.

Flow Breakdown

Call Volume

$4.5M

Put Volume

$216K

Flow Intent

DIRECTIONAL

Catalyst

Product Launch

More Bullish Flow · 2026-08-24

TGTX7/10 MRNA7/10 MRK7/10 SLS6/10 ROIV6/10 JNJ6/10

Engine-Selected Contract

The contract the engine priced for this row. Descriptive, not a recommendation.

ContractO:RVMD260918C00230000

Strike$230.00

Expiration2026-09-18

Delta0.28

Key Levels

Resistance$220.34

Support$178.07

Price$209.46

SMA 50 / 200$187 / $127

52W Range$34 — $220

RSI (14)62

News & Catalyst Analysis

Key Headline

Revolution Medicines Advances RASolve 308 Lung Cancer Trial, Raising Long-Term Upside Potential for RVMD

News Summary

Revolution Medicines is gaining momentum following news that it is advancing its RASolve 308 lung cancer trial, which analysts note significantly raises the long-term upside potential for the clinical-stage biotech firm. While the underlying stock experienced a minor consolidation of -1.1% to close at $209.46, institutional interest remains robust. This oncology pipeline progress is expected to draw continued high-volume call flow as milestones approach.

Flow Intent Analysis

The institutional call buying concentrated at an out-of-the-money strike ($230C) with a long duration (September 2026) ahead of major clinical milestones, indicating an anticipatory bet on long-term appreciation rather than immediate protection.

One email a week. Catch up in five minutes.

The GammaRips weekly briefing — engine state, the latest Lab experiment, and what the pool's outcome data showed. No firehose, no FOMO.

Read the 2026-08-24 morning briefing for the full scan this RVMD row came from: the shape of the pool that day, the themes in the flow, and every other name in it.

How We Read This Flow

Plain-English explainers on the methodology behind signals like this one.

View all →

One email a week. Catch up in five minutes.

RVMD

Key Headline

News Summary

Flow Intent Analysis

One email a week. Catch up in five minutes.

How We Read This Flow

How to Build an MCP Server for Options Trading

Options Block Trade vs Sweep: How to Spot Institutional Flow

How to Build an AI Agent for Options Trading